Choking hypoxia-inducible factor 1α: A novel mechanism for connective tissue growth factor ihibition of angiogenesis

Journal of the National Cancer Institute

Volumn 98, Issue 14, 2006, Pages 946-948

  Tosetti, Francesca ^a   Noonan, Douglas M ^b   Albini, Adriana ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LYSINE; MESSENGER RNA; OXYGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLINE; PROTEASOME; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN; ANGIOGENESIS INHIBITOR; IMMEDIATE EARLY PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTAXIS; CHONDROSARCOMA; CHROMOSOME 10; COLON CANCER; DIABETES MELLITUS; EDITORIAL; ENDOTHELIUM CELL; FIBROSIS; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; HYDROXYLATION; HYPERGLYCEMIA; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LUNG ADENOCARCINOMA; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MICROENVIRONMENT; NONHUMAN; NUCLEIC ACID PROBE; OXYGEN TENSION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT; WOUND HEALING; ADENOCARCINOMA; ANIMAL; DISEASE MODEL; LUNG TUMOR; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NOTE; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746777320     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj294     Document Type: Editorial

References (25)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
2. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005;65:10637-41.
3. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 2005;242: 157-213.
4. Esteban MA, Maxwell PH. HIF, a missing link between metabolism and cancer. Nat Med 2005;11:1047-8.
5. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
6. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71-103.
7. Semenza GL. HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001;107:1-3.
8. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111:709-20.
9. Chang C-C, Lin M-T, Lin B-R, Jeng Y-M, Chen S-T, Chu C-Y, et al. Effect of connective tissue growth factor on hypoxia-inducible factor 1α degradation and tumor angiogenesis. J Natl Cancer Inst 2006;98:984-95.
10. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/ nephroblastoma overexpressed (CCN) family. Endocr Rev 1999;20:189-206.
11. Lam S, van der Geest RN, Verhagen NA, van Nieuwenhoven FA, Blom IE, Aten J, et al. Connective tissue growth factor and IGF-1 are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 2003;52:2975-83.
12. Herbst R, Hidalgo M, Pierson A, Holden S, Bergen M, Eckhardt S. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 2002;29(1 Suppl 4):66-77.
13. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
14. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-74.
15. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005;11:992-7.
16. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004;96:364-75.
17. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
18. Kondo S, Kubota S, Mukudai Y, Moritani N, Nishida T, Matsushita H, et al. Hypoxic regulation of stability of connective tissue growth factor/ CCN2 mRNA by 3′-untranslated region interacting with a cellular protein in human chondrosarcoma cells. Oncogene 2006;25:1099-110.
19. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of CTGF is directly mediated by Hif-1. Am J Physiol Renal Physiol 2004;287:F1223-32.
20. Pinkas J, Teicher BA. TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol 2006 Mar 10 [Epub ahead of print].
21. Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM, Albini A. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the anti-angiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res 2005;11:4610-9.
22. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38527-35.
23. Piret JP, Mottet D, Raes M, Michiels C. Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002;64:889-92.
24. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-20.
25. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14.